These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 17185154

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, Akizawa T, Andreucci VE, Young EW, Port FK.
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [Abstract] [Full Text] [Related]

  • 5. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A, Covic A, Locatelli F, Macdougall IC, ORAMA study group.
    Ren Fail; 2008 May; 30(3):267-76. PubMed ID: 18350446
    [Abstract] [Full Text] [Related]

  • 6. [DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Spain].
    Piera L, Cruz JM, Braga-Gresham JL, Eichleay MA, Pisoni RL, Port FK.
    Nefrologia; 2007 May; 27(4):496-504. PubMed ID: 17944588
    [Abstract] [Full Text] [Related]

  • 7. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H, Mimura T, Honda N.
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [Abstract] [Full Text] [Related]

  • 8. [Study of immutable variables determining rHuEPO dose requirements on hemodialysis patients].
    Gascón A, Virto R, Lou LM, Pernaute R, Moreno R, Pérez J, Aladrén MJ, Moragrega B, Castillón E, Gómez R, Vives PJ, Alvarez R, García FJ, Castilla J, Gutiérrez Colón JA.
    Nefrologia; 2005 Oct; 25(5):535-42. PubMed ID: 16392304
    [Abstract] [Full Text] [Related]

  • 9. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.
    Ebben JP, Gilbertson DT, Foley RN, Collins AJ.
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1205-10. PubMed ID: 17699349
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dialyser reuse-associated mortality and hospitalization risk in incident Medicare haemodialysis patients, 1998-1999.
    Collins AJ, Liu J, Ebben JP.
    Nephrol Dial Transplant; 2004 May; 19(5):1245-51. PubMed ID: 14993497
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ.
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.